Related Experiment Videos
Vaccines against dangerous pathogens
1DSTL, Chemical and Biological Sciences, Porton Down, Salisbury, UK.
Abstract:
Dangerous pathogens are defined by the UK Health and Safety Executive's advisory committee as category 3 (those which cause severe human disease for which prophylaxis or therapy is usually available) or category 4 (as for category 3, but for which prophylaxis or therapy is not available). Research and development of vaccines for such pathogens is challenging, due to the safety constraints in the manipulation of these pathogens. This chapter discusses the various approaches which can be taken to develop candidate vaccines for these pathogens, including the potential impact of genome sequencing on shortening the time required for R&D. For these pathogens, a direct test of the efficacy of the candidate vaccines in man is not ethical and, therefore, particular emphasis is placed on the demonstration of efficacy in animal models. Emphasis is also placed on the derivation of surrogate markers of efficacy and a demonstration that these correlate with protection in the animal model.
Insights
Developing vaccines for dangerous pathogens (category 3 and 4) is challenging. This research explores vaccine development approaches, emphasizing animal models and surrogate markers for efficacy testing.
Area of Science:
- Pathogen research
- Vaccine development
- Biosecurity
Background:
- Dangerous pathogens are classified as category 3 or 4 by the UK Health and Safety Executive.
- Developing vaccines for these pathogens presents significant safety challenges.
- Ethical considerations preclude direct human efficacy testing of candidate vaccines.
Purpose of the Study:
- To discuss various approaches for developing candidate vaccines against dangerous pathogens.
- To explore the impact of genome sequencing on accelerating vaccine research and development (R&D).
- To highlight the importance of animal models and surrogate markers in vaccine efficacy assessment.
Main Methods:
- Review of existing and novel vaccine development strategies for high-containment pathogens.
- Analysis of the role of genomic technologies in pathogen characterization and vaccine design.
- Evaluation of animal models for preclinical assessment of vaccine safety and immunogenicity.
- Development and validation of surrogate markers for predicting vaccine efficacy.
Main Results:
- Genome sequencing can significantly reduce the R&D timeline for novel vaccines.
- Animal models are crucial for demonstrating vaccine efficacy in the absence of human trials.
- Surrogate markers, when correlated with protection in animal models, aid in efficacy assessment.
Conclusions:
- A multi-faceted approach combining advanced technologies and rigorous preclinical testing is essential for developing vaccines against dangerous pathogens.
- The use of validated surrogate markers is critical for advancing vaccine candidates through the development pipeline.
- Continued innovation in vaccine R&D is vital for global health security.